nach oben

Erschienen in:

14.01.2020 | Main topic

Cardiovascular disease in patients with chronic kidney disease

verfasst von: Dr. med. Turgay Saritas, Jürgen Floege

Erschienen in: Herz | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Patients with chronic kidney disease (CKD) are at increased risk for kidney failure, cardiovascular disease (CVD), and death. In fact, the likelihood of dying from CVD is markedly higher than that for reaching end-stage renal disease. Evidence-based management of comorbidities such as CVD remains challenging in patients with advanced CKD, as they were usually excluded from randomized controlled trials. This review focuses on the epidemiology, risk factors, and clinical manifestations of CVD in patients with advanced CKD. Specific topics of interest include diagnostic and therapeutic challenges of heart failure, coronary artery disease, and atrial fibrillation.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11(7):e158765PubMedPubMedCentral

Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P et al (2018) Comparison of the complexity of patients seen by different medical Subspecialists in a universal health care system. JAMA Netw Open 1(7):e184852PubMedPubMedCentral

Organization WH (2018) Mortality and global health estimates: causes of death; projections for 2015–2030; projection of death rates. WHO, Geneva

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C‑Y (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305PubMed

Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S et al (2015) Cause of death in patients with reduced kidney function. J Am Soc Nephrol 26(10):2504–2511PubMedPubMedCentral

Wanner C, Amann K, Shoji T (2016) The heart and vascular system in dialysis. Lancet 388(10041):276–284PubMed

Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521PubMedPubMedCentral

Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P (2014) Chronic kidney disease and premature ageing. Nat Rev Nephrol 10(12):732–742PubMed

Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB et al (2016) Development and validation of cardiovascular risk scores for haemodialysis patients. Int J Cardiol 216:68–77PubMed

10.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al (2016) Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728–741PubMed

11.

Cohen DL, Townsend RR (2008) What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker? J Clin Hypertens 10(10):803–804

12.

Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010) The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25(12):3977–3982PubMed

13.

Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS et al (2016) Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 31(2):255–261PubMed

14.

Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D et al (2014) Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant 29(5):1037–1047PubMed

15.

Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456–2463PubMed

16.

Mafham M, Haynes R (2018) PCSK9 inhibition: ready for prime time in CKD? Kidney Int 93(6):1267–1269PubMed

17.

Winkelmayer WC, Glynn RJ, Levin R, Owen WF Jr., Avorn J (2001) Determinants of delayed nephrologist referral in patients with chronic kidney disease. Am J Kidney Dis 38(6):1178–1184PubMed

18.

Wang X, Shapiro JI (2019) Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol 15(3):159–175PubMed

19.

McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A et al (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 5(3):309–314

20.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11(7):1277–1285PubMed

21.

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA et al (2002) Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40(1):41–46PubMed

22.

Reddy YNV, Obokata M, Dean PG, Melenovsky V, Nath KA, Borlaug BA (2017) Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 38(24):1913–1923PubMed

23.

Yamada S, Ishii H, Takahashi H, Aoyama T, Morita Y, Kasuga H et al (2010) Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. Clin J Am Soc Nephrol 5(10):1793–1798PubMedPubMedCentral

24.

Kramann R, Erpenbeck J, Schneider RK, Rohl AB, Hein M, Brandenburg VM et al (2014) Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol 25(10):2351–2365PubMedPubMedCentral

25.

House AA, Wanner C, Sarnak MJ, Pina IL, McIntyre CW, Komenda P et al (2019) Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95(6):1304–1317PubMed

26.

Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ et al (2015) beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 26(4):987–996PubMed

27.

Burnier M (2019) Should we eat more potassium to better control blood pressure in hypertension? Nephrol Dial Transplant 34(2):184–193

28.

Ellison DH, Terker AS (2015) Why your mother was right: how potassium intake reduces blood pressure. Trans Am Clin Climatol Assoc 126:46–55PubMedPubMedCentral

29.

Bae EH, Lim SY, Cho KH, Choi JS, Kim CS, Park JW et al (2012) GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. Am J Kidney Dis 59(6):795–802PubMed

30.

Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U et al (2010) Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 268(1):40–49PubMed

31.

Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M (2007) Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116(13):1465–1472PubMed

32.

Sharma R, Pellerin D, Gaze DC, Gregson H, Streather CP, Collinson PO et al (2005) Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 20(10):2207–2214PubMed

33.

Untersteller K, Girerd N, Duarte K, Rogacev KS, Seiler-Mussler S, Fliser D et al (2016) NT-proBNP and echocardiographic parameters for prediction of cardiovascular outcomes in patients with CKD stages G2-G4. Clin J Am Soc Nephrol 11(11):1978–1988PubMedPubMedCentral

34.

Wang LW, Fahim MA, Hayen A, Mitchell RL, Baines L, Lord S et al (2011) Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008691.pub2 CrossRefPubMed

35.

Winther S, Svensson M, Jorgensen HS, Bouchelouche K, Gormsen LC, Pedersen BB et al (2015) Diagnostic performance of coronary CT angiography and myocardial perfusion imaging in kidney transplantation candidates. JACC Cardiovasc Imaging 8(5):553–562PubMed

36.

Leyba K, Wagner B (2019) Gadolinium-based contrast agents: why nephrologists need to be concerned. Curr Opin Nephrol Hypertens 28(2):154–162PubMedPubMedCentral

37.

Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M et al (2018) Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can J Kidney Health Dis 5:2054358118778573PubMedPubMedCentral

38.

Rodby RA (2008) Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21(2):145–149PubMed

39.

Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies HJ, McIntyre CW (2012) Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol 7(8):1285–1292PubMedPubMedCentral

40.

Kraus D, von Jeinsen B, Tzikas S, Palapies L, Zeller T, Bickel C et al (2018) Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease. J Am Heart Assoc 7(19):e8032PubMedPubMedCentral

41.

Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28(2):653–659PubMed

42.

James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P et al (2011) Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123(4):409–416PubMed

43.

Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137(7):555–562PubMed

44.

Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M et al (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111(9):692–698PubMed

45.

Shaw C, Nitsch D, Lee J, Fogarty D, Sharpe CC (2016) Impact of an early invasive strategy versus conservative strategy for unstable angina and non-ST elevation acute coronary syndrome in patients with chronic kidney disease: a systematic review. PLoS ONE 11(5):e153478PubMedPubMedCentral

46.

Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA et al (2004) Survival after coronary revascularization among patients with kidney disease. Circulation 110(14):1890–1895PubMed

47.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA et al (2018) Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 39(24):2314–2325PubMedPubMedCentral

48.

Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY et al (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123(25):2946–2953PubMedPubMedCentral

49.

Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5):569–574PubMed

50.

Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22(2):349–357PubMedPubMedCentral

51.

Buiten MS, de Bie MK, Rotmans JI, Gabreels BA, van Dorp W, Wolterbeek R et al (2014) The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 100(9):685–690PubMed

52.

Holden RM, Booth SL (2007) Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 3(10):522–523PubMed

53.

Kidney Disease (2013) Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3:1–150

54.

Arrigo M, Cippà PE, Mebazaa A (2018) Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease. Curr Heart Fail Rep 15(5):307–314PubMed

55.

Stamellou E, Floege J (2018) Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 33(10):1683–1689PubMed

Titel: Cardiovascular disease in patients with chronic kidney disease
verfasst von: Dr. med. Turgay Saritas
Jürgen Floege
Publikationsdatum: 14.01.2020
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04884-0

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Die antagonistische Funktion des Herzmuskels

Grundlagen der Angiologie bei peripherer arterieller Verschlusskrankheit (pAVK)

Insufficient left ventricular unloading after extracorporeal membrane oxygenation

The bidirectional relationship between chronic obstructive pulmonary disease and coronary artery disease